Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

AstraZeneca
McKinsey
Boehringer Ingelheim
Mallinckrodt
Harvard Business School
Merck

Last Updated: January 27, 2023

CLINICAL TRIALS PROFILE FOR FENTORA


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Fentora

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00387010 ↗ Open-Label Study to Evaluate the Effect of Treatment With Fentanyl Buccal Tablets on Pain Anxiety Symptoms When Used for the Management of Breakthrough Pain Terminated Cephalon Phase 3 2006-12-01 The primary purpose of the study is to evaluate the impact of treatment with fentanyl buccal tablets on the anxiety symptoms commonly associated with chronic pain in patients with breakthrough pain (BTP). Other purposes are to assess the management of BTP, to evaluate patient functioning, and to determine any influences on the successful dose achieved.
NCT00685295 ↗ Fentanyl Administered Intraorally for Rapid Treatment of Orthopedic Pain Completed Massachusetts General Hospital Phase 1/Phase 2 2008-08-01 Assess whether transbuccal fentanyl provides more rapid relief of orthopedic pain, than does the comparator Percocet
NCT00842829 ↗ Study of Breakthrough Cancer Pain: Assessment of Fentanyl Buccal Tablets Titration and Treatment in Opioid-Tolerant Patients Terminated Cephalon Phase 4 2009-01-01 Breakthrough cancer pain (BTcP) is a common problem in patients with cancer. Fentanyl Buccal Tablet (FBT) is used for the treatment of BTP in adults with cancer who are already receiving maintenance opioid therapy for chronic cancer pain. FBT treatment should be individually titrated to an effective dose that provides adequate analgesia and minimizes undesirable effects. To reach the safest effective dose for the individual patient as soon as possible, the dose titration process is critical. The aim of this study, conducted under pragmatic conditions in a large-scale population of cancer patients is to compare the proportion of patients reaching an effective FBT dose after titration starting with either a 100 mcg dose or a 200 mcg dose.
NCT01007773 ↗ Safety of Dexmedetomidine in Severe Traumatic Brain Injury Withdrawn Hospira, Inc. Phase 2 2010-01-01 The aim of this study is to assess the safety and feasibility of dexmedetomidine as an adjunct to conventional sedative therapy compared to conventional sedative therapy alone in patients with severe traumatic brain injury.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Fentora

Condition Name

Condition Name for Fentora
Intervention Trials
Breakthrough Pain 2
Pain 2
Liver Fibrosis 1
Vasospasm, Intracranial 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Fentora
Intervention Trials
Breakthrough Pain 2
Stroke 1
Chronic Pain 1
Labor Pain 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Fentora

Trials by Country

Trials by Country for Fentora
Location Trials
United States 30
United Kingdom 1
Ireland 1
Spain 1
Germany 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Fentora
Location Trials
Pennsylvania 3
Georgia 2
Florida 2
Utah 2
Texas 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Fentora

Clinical Trial Phase

Clinical Trial Phase for Fentora
Clinical Trial Phase Trials
Phase 4 3
Phase 3 2
Phase 2/Phase 3 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Fentora
Clinical Trial Phase Trials
Completed 3
Withdrawn 3
Recruiting 3
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Fentora

Sponsor Name

Sponsor Name for Fentora
Sponsor Trials
Hospira, Inc. 3
Hospira, now a wholly owned subsidiary of Pfizer 3
Cephalon 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Fentora
Sponsor Trials
Other 11
Industry 8
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Mallinckrodt
McKesson
Colorcon
Johnson and Johnson
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.